IXICO PLC (LON:IXI) has secured an agreement to expand the scope of an existing clinical trial study contract with a top 10 pharmaceutical company.
The AIM-listed data science firm, which specialises in the neuroscience field, said the additional services provided from the expansion would increase the contract's value by £600,000 to £1.6mln over its three-year term.
READ: IXICO bags a £1mln contract
The contract, originally announced on 14 May, involved IXICO providing its technology-enabled imaging services in a natural history study of people with early manifestation of Huntington's disease to observe the natural progression of the disease.
As a result of the expansion, the firm said it would provide additional analysis based on advanced imaging modalities in the study.
In lunchtime trading Monday, IXICO shares were up 1.5% at 33p.
--Adds share price--